[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[3] |
LIU Saiyue, LYU Xiaoqin, ZHOU Yun.
Key points of investigation and report of suspected death of adverse drug reaction
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
|
[4] |
LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing.
Management of individual adverse drug reaction reports
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
|
[5] |
PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu.
Exploring the significance of collecting patient reports based on international pharmacovigilance experience
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
|
[6] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[7] |
.
Annual report of national adverse drug reaction monitoring (2022)
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 712-719.
|
[8] |
WU Yanyan, HU Xuelian, DAN Chonghui.
Analysis of one case of double knee joint pain induced by linezolid tablets
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 221-224.
|
[9] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[10] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[11] |
PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao.
Establishment of patient reporting scheme in the UK and its implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
|
[12] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[13] |
YANG Qiuyue, SU Jun, ZHANG Xue, XIE Jiangan.
Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1141-1147.
|
[14] |
LIU Yantao, ZHANG Lingli, LIN Yunzhu, CHEN Li, WANG Li.
Mining and research of adverse reaction signals of pneumonia vaccines based on US Vaccine Adverse Event Reporting System
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 96-100.
|
[15] |
WU Na, SU Dan, WANG Haikun, SHEN Aizong.
Quality evaluation of adverse drug reaction reports in oncology department based on weighted Topsis-rank-sum ratio method
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 101-105.
|